BACKGROUND Metastasis is the main reason leading to death in colorectal cancer(CRC)and about 25%of CRC patients developed metastasis when first diagnosed.Thus,unveiling biomarkers of CRC metastasis is of great signifi...BACKGROUND Metastasis is the main reason leading to death in colorectal cancer(CRC)and about 25%of CRC patients developed metastasis when first diagnosed.Thus,unveiling biomarkers of CRC metastasis is of great significance.AIM To reveal biomarkers of CRC metastasis.METHODS Weighted gene co-expression network analysis was conducted to identify metastatic biomarkers in CRC through a systematic analysis of the GSE29621 dataset.Comprehensive validation was performed subsequently using publicly available datasets from The Cancer Genome Atlas and Gene Expression Omnibus and supplemented with experimental verification in CRC cell lines.Moreover,the identified hub gene charged multivesicular body protein 7(CHMP7)was further subjected to clinical correlation analysis via Kaplan-Meier survival curves and Gene Set Enrichment Analysis to assess its prognostic significance and potential mechanistic involvement in CRC progression.RESULTS CHMP7 was identified as a key metastatic biomarker of CRC which displayed lower expression in CRC tissues,especially in CRC patients with metastasis and CRC cell lines with high metastasis potential.The expression of CHMP7 was significantly correlated with normal,metastatic tumor,pathologic stage,and lymphatic invasion(P<0.05).CRC patients with higher expression of CHMP7 exhibited better overall survival.Besides,Gene Set Enrichment Analysis results showed that CHMP7 might be involved in metastatic related pathways.CONCLUSION Our results indicate that CHMP7 might be a prognostic biomarker correlated with CRC metastasis.展开更多
Objective:To systematically evaluate the efficacy and safety of Qianliexin capsule combined with western medicine in benign prostatic hyperplasia treatment.Methods:Randomized controlled trials of Qianliexin capsule co...Objective:To systematically evaluate the efficacy and safety of Qianliexin capsule combined with western medicine in benign prostatic hyperplasia treatment.Methods:Randomized controlled trials of Qianliexin capsule combined with western medicine in the treatment of benign prostatic hyperplasia were searched from PubMed,the Cochrane Library,EMBASE,Web of Science,China National Knowledge Infrastructure,VIP,Wanfang and China Biomedical Literature Databases from establishment of the database to February 2021.Meta-analysis was performed using RevMan5.4 software after two researchers independently screened the literatures,extracted the data and evaluated the bias risks in the included studies according to the Cochrane Collaboration System Evaluator Manual.Results:6 randomized controlled trials involving 1060 patients were included.Meta-analysis results showed that the treatment group was better than the control group in total effective rate(Relative Risk=1.19,95%Confidence Interval(1.10,1.28),P<0.00001),International Prostate Symptom Score(Mean Difference=-2.99,95%confidence interval(-4.00,-1.99),P<0.00001),prostate volume(Mean Difference=-3.77,95%Confidence Interval(-4.67,-2.86),P<0.00001),postvoid residual urine volume(Mean Difference=-5.96,95%Confidence Interval(-8.15,-3.77),P<0.00001)and maximum urine flow rate(Mean Difference=3.45,95%Confidence Interval(2.53,4.37),P<0.00001).While there was no significant difference in the adverse effects rate(Relative Risk=0.71,95%Confidence Interval(0.33,1.56),P=0.40)between the treatment group and the control group.Conclusion:Qianliexin capsule combined with western medicine in the treatment of benign prostatic hyperplasia showed good efficacy and high safety.However,more high-quality and large-sample studies are needed to confirm the above conclusions.展开更多
Background:To systematically evaluate the efficacy and safety of the Chinese patent medicine Shuxuening injection combined with western medicine in vascular dementia treatment.Methods:Randomized controlled trials of t...Background:To systematically evaluate the efficacy and safety of the Chinese patent medicine Shuxuening injection combined with western medicine in vascular dementia treatment.Methods:Randomized controlled trials of the Chinese patent medicine Shuxuening injection in vascular dementia treatment is searched in the databases of CNKI,Wanfang,VIP,CBM,PubMed,The Cochrane Library,Embase and Web of Science from the establishment time to December 2020.After screen the literature,extract the data and evaluate the bias risk of studies included;tRevMan5.3 was used for met-analysis.Results:Nine randomized controlled trials including 932 patients were included.The results of meta-analysis included:(1)the total effective rate(RR=1.27,95%CI(1.18,1.36),P<0.00001);(2)MMSE score(MD=4.78,95%CI(1.75,7.80),P=0.002);(3)ADL score(MD=8.87,95%CI(6.70,11.05),P<0.00001);(4)NIHSS score(MD=−6.60,95%CI(−7.04,−6.16).P<0.00001).The results of meta-analysis of the test group are better than those in the control group.Conclusion:The Chinese patent medicine Shuxuening injection combined with conventional western medicine has showed some advantages in the total effective rate,MMSE score,ADL score,NIHSS score than conventional western medicine without more side effects in vascular dementia treatment.More randomized,double-blind,large sample clinical studies are needed to confirm the above conclusions.展开更多
基金Supported by the National Natural Science Foundation of China,No.82260715the Middle-Aged and Young Teachers in Colleges and Universities in Guangxi Basic Ability Promotion Project,No.2024KY0302+2 种基金Guangxi Collaborative Innovation Center for Research on Functional Ingredients of Agricultural Residues,No.CICAR2016-P6the Grant of Research Project on High-Level Talents of Youjiang Medical College for Nationalities,No.YY2021SK002Key Laboratory of Pollution Exposure and Health Intervention of Zhejiang Province,No.202300011.
文摘BACKGROUND Metastasis is the main reason leading to death in colorectal cancer(CRC)and about 25%of CRC patients developed metastasis when first diagnosed.Thus,unveiling biomarkers of CRC metastasis is of great significance.AIM To reveal biomarkers of CRC metastasis.METHODS Weighted gene co-expression network analysis was conducted to identify metastatic biomarkers in CRC through a systematic analysis of the GSE29621 dataset.Comprehensive validation was performed subsequently using publicly available datasets from The Cancer Genome Atlas and Gene Expression Omnibus and supplemented with experimental verification in CRC cell lines.Moreover,the identified hub gene charged multivesicular body protein 7(CHMP7)was further subjected to clinical correlation analysis via Kaplan-Meier survival curves and Gene Set Enrichment Analysis to assess its prognostic significance and potential mechanistic involvement in CRC progression.RESULTS CHMP7 was identified as a key metastatic biomarker of CRC which displayed lower expression in CRC tissues,especially in CRC patients with metastasis and CRC cell lines with high metastasis potential.The expression of CHMP7 was significantly correlated with normal,metastatic tumor,pathologic stage,and lymphatic invasion(P<0.05).CRC patients with higher expression of CHMP7 exhibited better overall survival.Besides,Gene Set Enrichment Analysis results showed that CHMP7 might be involved in metastatic related pathways.CONCLUSION Our results indicate that CHMP7 might be a prognostic biomarker correlated with CRC metastasis.
文摘Objective:To systematically evaluate the efficacy and safety of Qianliexin capsule combined with western medicine in benign prostatic hyperplasia treatment.Methods:Randomized controlled trials of Qianliexin capsule combined with western medicine in the treatment of benign prostatic hyperplasia were searched from PubMed,the Cochrane Library,EMBASE,Web of Science,China National Knowledge Infrastructure,VIP,Wanfang and China Biomedical Literature Databases from establishment of the database to February 2021.Meta-analysis was performed using RevMan5.4 software after two researchers independently screened the literatures,extracted the data and evaluated the bias risks in the included studies according to the Cochrane Collaboration System Evaluator Manual.Results:6 randomized controlled trials involving 1060 patients were included.Meta-analysis results showed that the treatment group was better than the control group in total effective rate(Relative Risk=1.19,95%Confidence Interval(1.10,1.28),P<0.00001),International Prostate Symptom Score(Mean Difference=-2.99,95%confidence interval(-4.00,-1.99),P<0.00001),prostate volume(Mean Difference=-3.77,95%Confidence Interval(-4.67,-2.86),P<0.00001),postvoid residual urine volume(Mean Difference=-5.96,95%Confidence Interval(-8.15,-3.77),P<0.00001)and maximum urine flow rate(Mean Difference=3.45,95%Confidence Interval(2.53,4.37),P<0.00001).While there was no significant difference in the adverse effects rate(Relative Risk=0.71,95%Confidence Interval(0.33,1.56),P=0.40)between the treatment group and the control group.Conclusion:Qianliexin capsule combined with western medicine in the treatment of benign prostatic hyperplasia showed good efficacy and high safety.However,more high-quality and large-sample studies are needed to confirm the above conclusions.
文摘Background:To systematically evaluate the efficacy and safety of the Chinese patent medicine Shuxuening injection combined with western medicine in vascular dementia treatment.Methods:Randomized controlled trials of the Chinese patent medicine Shuxuening injection in vascular dementia treatment is searched in the databases of CNKI,Wanfang,VIP,CBM,PubMed,The Cochrane Library,Embase and Web of Science from the establishment time to December 2020.After screen the literature,extract the data and evaluate the bias risk of studies included;tRevMan5.3 was used for met-analysis.Results:Nine randomized controlled trials including 932 patients were included.The results of meta-analysis included:(1)the total effective rate(RR=1.27,95%CI(1.18,1.36),P<0.00001);(2)MMSE score(MD=4.78,95%CI(1.75,7.80),P=0.002);(3)ADL score(MD=8.87,95%CI(6.70,11.05),P<0.00001);(4)NIHSS score(MD=−6.60,95%CI(−7.04,−6.16).P<0.00001).The results of meta-analysis of the test group are better than those in the control group.Conclusion:The Chinese patent medicine Shuxuening injection combined with conventional western medicine has showed some advantages in the total effective rate,MMSE score,ADL score,NIHSS score than conventional western medicine without more side effects in vascular dementia treatment.More randomized,double-blind,large sample clinical studies are needed to confirm the above conclusions.
